Literature DB >> 2720692

Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy.

G Los1, P H Mutsaers, W J van der Vijgh, G S Baldew, P W de Graaf, J G McVie.   

Abstract

Chemotherapy i.p. is increasingly being tested as a treatment modality for cancer limited to the peritoneal cavity. We have developed a rat tumor model in which penetration and distribution of cis-diamminedichloroplatinum(II) into intraperitoneal tumors have been studied. The platinum concentration in intraperitoneal tumor nodules, measured by two techniques, flameless atomic absorption spectroscopy and proton-induced X-ray emission, was always higher after i.p. treatment than i.v. Further, platinum concentrations were higher at the periphery of the tumor after i.p. administration than after i.v., while platinum concentrations in the center of the tumor nodules were identical. No difference was detected in platinum concentrations in s.c. tumors nor in the total area under the curve (plasma) after i.p. and i.v. administration of cis-diamminedichloroplatinum(II), suggesting that the higher drug concentration measured in peritoneal tumors after i.p. administration is due to direct diffusion of the drug from the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  70 in total

Review 1.  Intraperitoneal chemotherapy for ovarian cancer.

Authors:  Gregory Friberg; Gini Fleming
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

2.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

3.  High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.

Authors:  Philippe Esquis; David Consolo; Guy Magnin; Philippe Pointaire; Philippe Moretto; Maria Dolores Ynsa; Jean-Luc Beltramo; Carole Drogoul; Michel Simonet; Laurent Benoit; Patrick Rat; Bruno Chauffert
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Description of a novel approach for intraperitoneal drug delivery and the related device.

Authors:  Wiebke Solaß; Alexander Hetzel; Giorgi Nadiradze; Emil Sagynaliev; Marc A Reymond
Journal:  Surg Endosc       Date:  2012-05-12       Impact factor: 4.584

Review 5.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

6.  Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Authors:  Dhaval K Shah; Beom Soo Shin; Jean Veith; Karoly Tóth; Ralph J Bernacki; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2009-02-20       Impact factor: 4.030

7.  Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.

Authors:  D S Alberts; M Markman; F Muggia; R F Ozols; E Eldermire; M A Bookman; T Chen; J Curtin; L M Hess; L Liebes; R C Young; E Trimble
Journal:  Gynecol Oncol       Date:  2006-10-27       Impact factor: 5.482

8.  Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.

Authors:  M Markman; B Reichman; T Hakes; R Barakat; J Curtin; S Rubin; W Jones; J L Lewis; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 9.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.

Authors:  Maurie Markman; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.